Plasma Cell Leukemia in the Era of Novel Agent Therapy

Dr. Wilson Gonsalves, an Associate Professor of Medicine in Hematology at Mayo Clinic in Rochester, MN, discusses his article appearing in the March 2021 issue of Mayo Clinic Proceedings, where looking at primary plasma cell leukemia, an aggressive form of multiple myeloma with dismal overall survival outcomes, he evaluated the clinical outcomes of patients when defined by the new recommendations of greater than 5% circulating clonal plasma cells on peripheral blood smear and treated with novel agent induction therapies. He noted some patients have better than expected survival and this phenomenon may be influenced by the absence of high-risk cytogenetics. Available at: https://mayocl.in/3nDdK2H